Advertisement

UC Surveillance

  • Chang-Ho Ryan Choi
  • Ibrahim Al-Bakir
Chapter

Abstract

Patients with inflammatory bowel disease (IBD) have a significant risk of developing colorectal cancer (CRC). Regular colonoscopic surveillance and dysplasia detection remains the mainstay of CRC risk management. The efficacy of colonoscopic surveillance in preventing CRC remains poor with a considerable number of surveillance patients presenting with interval or advanced CRC. This chapter will focus on clinical and molecular risk factors associated with CRC development. A particular consideration will be given to challenges in detecting and managing dysplasia, with reference to our latest understanding of how CRC evolves from a molecular perspective that could ultimately pave the way for biomarker discovery.

References

  1. 1.
    Crohn B, Rosenberg H. The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Am J Med Sci. 1925;170:220–8.CrossRefGoogle Scholar
  2. 2.
    Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48(4):526–35.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Choi C-HR, Rutter MD, Askari A, Lee GH, Warusavitarne J, Moorghen M, et al. Forty-year analysis of colonoscopic surveillance program for neoplasia in ulcerative colitis: an updated overview. Am J Gastroenterol. 2015;110(7):1022–34.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Jess T, Simonsen J, Jørgensen KT, Pedersen BV, Nielsen NM, Frisch M. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012;143(2):375–81. quiz e13-4.PubMedCrossRefGoogle Scholar
  5. 5.
    Mooiweer E, van der Meulen-de Jong AE, Ponsioen CY, Fidder HH, Siersema PD, Dekker E, et al. Chromoendoscopy for surveillance in inflammatory bowel disease does not increase neoplasia detection compared with conventional colonoscopy with random biopsies: results from a large retrospective study. Am J Gastroenterol. 2015;110(7):1014–21.PubMedCrossRefGoogle Scholar
  6. 6.
    Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323(18):1228–33.PubMedCrossRefGoogle Scholar
  7. 7.
    Gyde SN, Prior P, Allan RN, Stevens A, Jewell DP, Truelove SC, et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut. 1988;29(2):206–17.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126(2):451–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Bodian C, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2008;133(4):1099–341.CrossRefGoogle Scholar
  10. 10.
    Rubin DT, Huo D, Kinnucan JA, Sedrak MS, McCullom NE, Bunnag AP, et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case–control study. Clin Gastroenterol Hepatol. 2013;11(12):1601–1608.e4.PubMedCrossRefGoogle Scholar
  11. 11.
    Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004;53(12):1813–6.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Lashner BA, Turner BC, Bostwick DG, Frank PH, Hanauer SB. Dysplasia and cancer complicating strictures in ulcerative colitis. Dig Dis Sci. 1990;35(3):349–52.PubMedCrossRefGoogle Scholar
  13. 13.
    Gumaste V, Sachar DB, Greenstein AJ. Benign and malignant colorectal strictures in ulcerative colitis. Gut. 1992;33(7):938–41.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002;56(1):48–54.PubMedCrossRefGoogle Scholar
  15. 15.
    Broomé U, Löfberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology. 1995;22(5):1404–8.PubMedGoogle Scholar
  16. 16.
    Askling J, Dickman PW, Karlén P, Broström O, Lapidus A, Löfberg R, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology. 2001;120(6):1356–62.PubMedCrossRefGoogle Scholar
  17. 17.
    Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2000;14(2):145–53.PubMedCrossRefGoogle Scholar
  18. 18.
    Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Choi C-HR, Al Bakir I, Ding N-S(J), Lee G-H, Askari A, Warusavitarne J, et al. Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study. Gut. 2019;68:414–22.CrossRefGoogle Scholar
  20. 20.
    Velayos FS, Loftus EV, Jess T, Harmsen WS, Bida J, Zinsmeister AR, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology. 2006;130(7):1941–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJW, Evans GD, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59(5):666–89.PubMedCrossRefGoogle Scholar
  22. 22.
    Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology. 2003;124(2):544–60.PubMedCrossRefGoogle Scholar
  23. 23.
    Baars JE, Looman CWN, Steyerberg EW, Beukers R, Tan ACITL, Weusten BLAM, et al. The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case–control study. Am J Gastroenterol. 2011;106(2):319–28.PubMedCrossRefGoogle Scholar
  24. 24.
    Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006;130(4):1030–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Gilat T, Fireman Z, Grossman A, Hacohen D, Kadish U, Ron E, et al. Colorectal cancer in patients with ulcerative colitis. A population study in central Israel. Gastroenterology. 1988;94(4):870–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Nuako KW, Ahlquist DA, Mahoney DW, Schaid DJ, Siems DM, Lindor NM. Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. Gastroenterology. 1998;115(5):1079–83.PubMedCrossRefGoogle Scholar
  27. 27.
    Krugliak Cleveland N, Rubin DT, Hart J, Weber CR, Meckel K, Tran AL, et al. Patients with ulcerative colitis and primary sclerosing cholangitis frequently have subclinical inflammation in the proximal colon. Clin Gastroenterol Hepatol. 2018;16(1):68–74.PubMedCrossRefGoogle Scholar
  28. 28.
    Shetty K, Rybicki L, Brzezinski A, Carey WD, Lashner BA. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol. 1999;94(6):1643–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Venkatesh PGK, Jegadeesan R, Gutierrez NG, Sanaka MR, Navaneethan U. Natural history of low grade dysplasia in patients with primary sclerosing cholangitis and ulcerative colitis. J Crohns Colitis. 2013;7(12):968–73.PubMedCrossRefGoogle Scholar
  30. 30.
    Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100(6):1345–53.PubMedCrossRefGoogle Scholar
  31. 31.
    Nguyen GC, Gulamhusein A, Bernstein CN. 5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations. Am J Gastroenterol. 2012;107(9):1298–304, 1305.PubMedCrossRefGoogle Scholar
  32. 32.
    Jess T, Lopez A, Andersson M, Beaugerie L, Peyrin-Biroulet L. Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis. Clin Gastroenterol Hepatol. 2014;12(11):1793–1800.e1.PubMedCrossRefGoogle Scholar
  33. 33.
    Levesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010;340(mar12 1):b5087.PubMedCrossRefGoogle Scholar
  34. 34.
    Eaden JA, Mayberry JF. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut. 2002;51(Suppl 5):V10–2.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastroenterology. 2015;148(3):639–651.e28.PubMedCrossRefGoogle Scholar
  36. 36.
    Rutter MD, Saunders BP, Wilkinson KH, Kamm MA, Williams CB, Forbes A. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc. 2004;60(3):334–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Rubin DT, Rothe JA, Hetzel JT, Cohen RD, Hanauer SB. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc. 2007;65(7):998–1004.PubMedCrossRefGoogle Scholar
  38. 38.
    Subramanian V, Ramappa V, Telakis E, Mannath J, Jawhari AU, Hawkey CJ, et al. Comparison of high definition with standard white light endoscopy for detection of dysplastic lesions during surveillance colonoscopy in patients with colonic inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(2):350–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Rutter MD, Saunders BP, Schofield G, Forbes A, Price AB, Talbot IC. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut. 2004;53(2):256–60.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Kiesslich R, Fritsch J, Holtmann M, Koehler HH, Stolte M, Kanzler S, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology. 2003;124(4):880–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Marion JF, Waye JD, Present DH, Israel Y, Bodian C, Harpaz N, et al. Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol. 2008;103(9):2342–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Ignjatovic A, East JE, Subramanian V, Suzuki N, Guenther T, Palmer N, et al. Narrow band imaging for detection of dysplasia in colitis: a randomized controlled trial. Am J Gastroenterol. 2012;107(6):885–90.PubMedCrossRefGoogle Scholar
  43. 43.
    Carballal S, Maisterra S, López-Serrano A, Gimeno-García AZ, Vera MI, Marín-Garbriel JC, et al. Real-life chromoendoscopy for neoplasia detection and characterisation in long-standing IBD. Gut. 2018;67(1):70–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Choi CR, Ignjatovic-Wilson A, Askari A, Lee GH, Warusavitarne J, Moorghen M, et al. Low-grade dysplasia in ulcerative colitis: risk factors for developing high-grade dysplasia or colorectal cancer. Am J Gastroenterol. 2015;110(10):1461.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Bernstein CN. ALMs versus DALMs in ulcerative colitis: polypectomy or colectomy? Gastroenterology. 1999;117(6):1488–92.PubMedCrossRefGoogle Scholar
  46. 46.
    Smith L-A, Baraza W, Tiffin N, Cross SS, Hurlstone DP. Endoscopic resection of adenoma-like mass in chronic ulcerative colitis using a combined endoscopic mucosal resection and cap assisted submucosal dissection technique. Inflamm Bowel Dis. 2008;14(10):1380–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Rubin PH, Friedman S, Harpaz N, Goldstein E, Weiser J, Schiller J, et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology. 1999;117(6):1295–300.PubMedCrossRefGoogle Scholar
  48. 48.
    Vieth M, Behrens H, Stolte M. Sporadic adenoma in ulcerative colitis: endoscopic resection is an adequate treatment. Gut. 2006;55(8):1151–5.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Wanders LK, Dekker E, Pullens B, Bassett P, Travis SPL, East JE. Cancer risk after resection of polypoid dysplasia in patients with longstanding ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol. 2014;12(5):756–64.PubMedCrossRefGoogle Scholar
  50. 50.
    Marion JF, Sands BE. The SCENIC consensus statement on surveillance and management of dysplasia in inflammatory bowel disease: praise and words of caution. Gastroenterology. 2015;148(3):462–7.PubMedCrossRefGoogle Scholar
  51. 51.
    Fumery M, Dulai PS, Gupta S, Prokop LJ, Ramamoorthy S, Sandborn WJ, et al. Incidence, risk factors, and outcomes of colorectal cancer in patients with ulcerative colitis with low-grade dysplasia: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15(5):665–674.e5.PubMedCrossRefGoogle Scholar
  52. 52.
    Galandiuk S, Rodriguez-Justo M, Jeffery R, Nicholson AM, Cheng Y, Oukrif D, et al. Field cancerization in the intestinal epithelium of patients with Crohn’s ileocolitis. Gastroenterology. 2012;142(4):855–864.e8.PubMedCrossRefGoogle Scholar
  53. 53.
    Salk JJ, Salipante SJ, Risques RA, Crispin DA, Li L, Bronner MP, et al. Clonal expansions in ulcerative colitis identify patients with neoplasia. Proc Natl Acad Sci U S A. 2009;106(49):20871–6.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Salk JJ, Bansal A, Lai LA, Crispin DA, Ussakli CH, Horwitz MS, et al. Clonal expansions and short telomeres are associated with neoplasia in early-onset, but not late-onset, ulcerative colitis. Inflamm Bowel Dis. 2013;19(12):2593–602.PubMedCrossRefGoogle Scholar
  55. 55.
    Yaeger R, Shah MA, Miller VA, Kelsen JR, Wang K, Heins ZJ, et al. Genomic alterations observed in colitis-associated cancers are distinct from those found in sporadic colorectal cancers and vary by type of inflammatory bowel disease. Gastroenterology. 2016;151(2):278–287.e6.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Brentnall TA, Crispin DA, Rabinovitch PS, Haggitt RC, Rubin CE, Stevens AC, et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology. 1994;107(2):369–78.PubMedCrossRefGoogle Scholar
  57. 57.
    Vermeulen L, Morrissey E, van der HM, Nicholson AM, Sottoriva A, Buczacki S, et al. Defining stem cell dynamics in models of intestinal tumor initiation. Science. 2013;342(6161):995–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Shenoy AK, Fisher RC, Butterworth EA, Pi L, Chang LJ, Appelman HD, et al. Transition from colitis to cancer: high Wnt activity sustains the tumor-initiating potential of colon cancer stem cell precursors. Cancer Res. 2012;72(19):5091–100.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Miyoshi H, Ajima R, Luo CT, Yamaguchi TP, Stappenbeck TS, Stappenbeck TS, et al. Wnt5a potentiates TGF-β signaling to promote colonic crypt regeneration after tissue injury. Science. 2012;338(6103):108–13.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–21.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Alexandrov LB, Jones PH, Wedge DC, Sale JE, Campbell PJ, Nik-Zainal S, et al. Clock-like mutational processes in human somatic cells. Nat Genet. 2015;47(12):1402–7.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Issa JPJ, Ahuja N, Toyota M, Bronner MP, Brentnall TA. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 2001;61(9):3573–7.PubMedGoogle Scholar
  63. 63.
    Risques RA, Lai LA, Himmetoglu C, Ebaee A, Li L, Feng Z, et al. Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation. Cancer Res. 2011;71(5):1669–79.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    O’Sullivan JN, Bronner MP, Brentnall TA, Finley JC, Shen W-TT, Emerson S, et al. Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat Genet. 2002;32(2):280–4.PubMedCrossRefGoogle Scholar
  65. 65.
    Iqbal T, Beggs A, Taniere P, Wallis Y, Mehta S, Magill L, et al. OP002 Epigenetic biomarkers to detect ulcerative colitis-associated neoplasia: results from phase I of the ENDCAP-C study. J Crohns Colitis. 2017;11(Sup 1):S1–2.CrossRefGoogle Scholar
  66. 66.
    Shigaki K, Mitomi H, Fujimori T, Ichikawa K, Tomita S, Imura J, et al. Immunohistochemical analysis of chromogranin A and p53 expressions in ulcerative colitis-associated neoplasia: Neuroendocrine differentiation as an early event in the colitis-neoplasia sequence. Hum Pathol. 2013;44(11):2393–9.PubMedCrossRefGoogle Scholar
  67. 67.
    Chen R, Pan S, Lai K, Lai LA, Crispin DA, Bronner MP, et al. Up-regulation of mitochondrial chaperone TRAP1 in ulcerative colitis associated colorectal cancer. World J Gastroenterol. 2014;20(45):17037–48.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Van Schaik FDM, Oldenburg B, Offerhaus GJA, Schipper MEI, Vleggaar FP, Siersema PD, et al. Role of immunohistochemical markers in predicting progression of dysplasia to advanced neoplasia in patients with ulcerative colitis. Inflamm Bowel Dis. 2012;18(3):480–8.PubMedCrossRefGoogle Scholar
  69. 69.
    D’Incà R, Cardin R, Benazzato L, Angriman I, Martines D, Sturniolo GC. Oxidative DNA damage in the mucosa of ulcerative colitis increases with disease duration and dysplasia. Inflamm Bowel Dis. 2004;10(1):23–7.PubMedCrossRefGoogle Scholar
  70. 70.
    Söderlund S, Tribukait B, Åst Ö, Broström O, Karlén P, Löfberg R, et al. Colitis-associated DNA aneuploidy and dysplasia in Crohn’s disease and risk of colorectal cancer. Inflamm Bowel Dis. 2011;17(5):1101–7.PubMedCrossRefGoogle Scholar
  71. 71.
    Rubin CE, Haggitt RC, Burmer GC, Brentnall TA, Stevens AC, Levine DS, et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology. 1992;103(5):1611–20.PubMedCrossRefGoogle Scholar
  72. 72.
    Lai LA, Risques RA, Bronner MP, Rabinovitch PS, Crispin D, Chen R, et al. Pan-colonic field defects are detected by CGH in the colons of UC patients with dysplasia/cancer. Cancer Lett. 2012;320(2):180–8.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Tsai J-H, Rabinovitch PS, Huang D, Small T, Mattis AN, Kakar S, et al. Association of aneuploidy and flat dysplasia with development of high-grade dysplasia or colorectal cancer in patients with inflammatory bowel disease. Gastroenterology. 2017;153(6):1492–1495.e4.PubMedCrossRefGoogle Scholar
  74. 74.
    Choi W-T, Rabinovitch PS, Wang D, Westerhoff M, et al. Outcome of “indefinite for dysplasia” in inflammatory bowel disease: Correlation with DNA flow cytometry and other risk factors of colorectal cancer. Hum Pathol. 2015;46(7):939–47.PubMedCrossRefGoogle Scholar
  75. 75.
    Garrity-Park MM, Loftus EVJ, Sandborn WJ, Bryant SC, Smyrk TC. Methylation status of genes in non-neoplastic mucosa from patients with ulcerative colitis-associated colorectal cancer. Am J Gastroenterol. 2010;105(7):1610–9.PubMedCrossRefGoogle Scholar
  76. 76.
    Toiyama Y, Okugawa Y, Tanaka K, Araki T, Uchida K, Hishida A, et al. A panel of methylated microRNA biomarkers for identifying high-risk patients with ulcerative colitis-associated colorectal cancer. Gastroenterology. 2017;153(6):1634–1646.e8.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Pekow J, Dougherty U, Huang Y, Gometz E, Nathanson J, Cohen G, et al. Gene signature distinguishes patients with chronic ulcerative colitis harboring remote neoplastic lesions. Inflamm Bowel Dis. 2013;19(3):461–70.PubMedCrossRefGoogle Scholar
  78. 78.
    Watanabe T, Kobunai T, Yamamoto Y, Ikeuchi H, Matsuda K, Ishihara S, et al. Predicting ulcerative colitis-associated colorectal cancer using reverse-transcription polymerase chain reaction analysis. Clin Colorectal Cancer. 2011;10(2):134–41.PubMedCrossRefGoogle Scholar
  79. 79.
    McCoy AN, Araujo-Perez F, Azcarate-Peril A, Yeh JJ, Sandler RS, Keku TO. Fusobacterium is associated with colorectal adenomas. PLoS One. 2013;8(1):e53653.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Strauss J, Kaplan GG, Beck PL, Rioux K, Panaccione R, Devinney R, et al. Invasive potential of gut mucosa-derived fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis. 2011;17(9):1971–8.PubMedCrossRefGoogle Scholar
  81. 81.
    Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012;22(2):292–8.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan T-J, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012;338(6103):120–3.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, et al. A decrease of the butyrate-producing species roseburia hominis and faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63(8):1275–83.CrossRefGoogle Scholar
  84. 84.
    Chen W, Liu F, Ling Z, Tong X, Xiang C. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS One. 2012;7(6):e39743.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Uronis JM, Muhlbauer M, Herfarth HH, Rubinas TC, Jones GS, Jobin C. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS One. 2009;4(6):e6026.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Zhan Y, Chen P-J, Sadler WD, Wang F, Poe S, Nunez G, et al. Gut microbiota protects against gastrointestinal tumorigenesis caused by epithelial injury. Cancer Res. 2013;73(24):7199–210.PubMedCrossRefGoogle Scholar
  87. 87.
    Tahara T, Hirata I, Nakano N, Tahara S. Potential link between Fusobacterium enrichment and DNA methylation accumulation in the inflammatory colonic mucosa in ulcerative colitis. Oncotarget. 2017;8(37):61917–26.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Zallot C, Peyrin-Biroulet L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep. 2013;15:315.PubMedCrossRefGoogle Scholar
  89. 89.
    Li X, Galipeau PC, Paulson TG, Sanchez CA, Arnaudo J, Liu K, et al. Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett’s esophagus. Cancer Prev Res (Phila). 2014;7(1):114–27.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Chang-Ho Ryan Choi
    • 1
  • Ibrahim Al-Bakir
    • 2
    • 3
  1. 1.St. George HospitalSydneyAustralia
  2. 2.Inflammatory Bowel Disease Unit, St. Marks’ HospitalHarrowUK
  3. 3.Cancer and Evolution Laboratory, Barts Cancer InstituteQueen Mary University of LondonLondonUK

Personalised recommendations